A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease CCR5 expression and improve natural killer cell function ex vivo. Aprepitant is a NK1R antagonist approved by FDA as an antiemetic.We conducted a phase IB randomized, placebo controlled, double...

Full description

Bibliographic Details
Main Authors: Pablo Tebas, Florin Tuluc, Jeffrey S Barrett, Wayne Wagner, Deborah Kim, Huaquing Zhao, René Gonin, James Korelitz, Steven D Douglas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3169584?pdf=render

Internet

http://europepmc.org/articles/PMC3169584?pdf=render

Similar Items